Mount Sinai’s Novel Biomarker Predicts Treatment Outcome in Ovarian Cancer Using Ingenuity Pathway Analysis from QIAGEN
27 Oct 2014New work from John Martignetti and his lab identified a novel prognostic biomarker indicating whether a patient will respond well or poorly to the standard chemotherapy used for ovarian cancer. The biomarker, which had not previously been linked to ovarian cancer, was found with QIAGEN’s Ingenuity Pathway Analysis (IPA), a leading application for interpreting biological data and modeling complex networks. Now scientists are studying how the biomarker, interferon regulatory factor 1 (IRF1), functions and whether upregulating it might improve ovarian cancer patients’ outcome in the future.
Related products
Request Quote for All Products
IPA- Integrate and understand complex 'omics data
Ingenuity Systems Inc.Comprehensive pathway and network analysis of complex 'omics data Peer Reviewed and Widely Adopted: IPA has been broadly adopted by the life science research community and is cited in thousands of peer-reviewed journal articles. Understand Complex ‘Omics Data:IPA helps you understand complex ‘omics data at multiple levels by integrating data from a variety of experimental platforms and providing insight into the molecular and chemical interactions, cellular phenotypes, and disease processes of your system. Discover Causal Connections. Faster. NEW:IPA helps you discover plausible signaling cascades by auto-generating regulatory networks which describe potential mechanisms of action predicted to explain the gene expression changes in your dataset. Unlock the Value of your Experiments:Analyze, integrate, and understand data derived from gene expression, microRNA, and SNP microarrays; metabolomics, proteomics, and RNA-Seq experiments; and small-scale experiments that generate gene and chemical lists with IPA.